Mechanisms of molecular carcinogenesis. Volume 2 /

• Other Authors: Haybaeck, Johannes (Editor)
• Format: Electronic eBook
• Language: English
• Published: Cham, Switzerland : Springer, 2017.
• Subjects: Carcinogenesis > Molecular aspects.; elektronické knihy; electronic books
• ISBN: 9783319536613; 9783319536606
• Physical Description: 1 online resource : color illustrations

Together with Volume 1, this book provides an inclusive overview of the molecular and cellular mechanisms of carcinogenesis and offers comprehensive insights into related clinical and therapeutic aspects. This second volume complements the first by presenting and concisely explaining the carcinogene...

Table of Contents:

• Preface; Contents; 1: Molecular Classification of Breast Cancer; 1.1 Introduction; 1.2 Histopathological Classification of In Situ and Invasive Breast Cancer; 1.2.1 Histological Features of Ductal Carcinoma In Situ; 1.2.2 Histological Types and Grade of Invasive Breast Cancers; 1.3 Molecular Classification of Invasive Breast Carcinoma; 1.3.1 Gene Expression Profiling in Breast Cancer; 1.3.2 Immunohistochemical Surrogates for Intrinsic Subtypes; 1.3.3 Genome Profiling in Breast Cancer; 1.3.4 Special Subtypes; 1.3.5 Familial Breast Cancer.
• 1.4 Molecular Classification of Ductal Carcinoma In Situ1.4.1 Molecular Subtypes in DCIS; 1.5 Future Perspectives; References; 2: Nonmelanoma Skin Cancer Actinic Keratosis and Squamous Cell Carcinoma; 2.1 Introduction; 2.2 Histological Classifications; 2.3 Influencing Factors for Carcinogenesis; 2.3.1 UV Radiation; 2.3.2 Inflammation and Cancer; 2.4 Immune Cells in Tumor Genesis; 2.4.1 Innate Immune Cells; 2.4.2 Adaptive Immune Cells; 2.4.3 Tumor Microenvironment; 2.5 Hypoxia or Oxidative Stress and Inflammation; 2.6 Viral Infection; 2.6.1 Acute and Chronic Viral Infection.
• 2.6.2 Treatment: Actinic Keratosis2.7 Targeted Therapies in AK; 2.7.1 5 Fluorouracil (5-FU); 2.7.2 Imiquimod; 2.7.3 Cyclooxygenase (COX)-2 Inhibitors; 2.7.4 Ingenol Mebutate; 2.7.5 Photodynamic Therapy (PDT); 2.7.6 Treatment: Cutaneous Squamous Cell Cancer; 2.8 Future (Targeted) Therapies or Treatment Options Used in Clinical Studies; 2.8.1 Anti-epidermal Growth Factor Receptors (EGFR); References; 3: Molecular Pathogenesis of Bone Tumours; 3.1 Introduction; 3.2 Tumour Types; 3.2.1 Cartilage Tumours; 3.2.2 Osteogenic Tumours; 3.2.3 Ewing Sarcoma; 3.2.4 Haematopoietic Tumours.
• 3.2.5 Giant Cell Tumours3.2.6 Notochordal Tumours (Chordoma); 3.2.7 Tumours of Undefined Neoplastic Nature; 3.2.7.1 Aneurysmal Bone Cysts; 3.2.7.2 Simple Bone Cyst; 3.2.7.3 Fibrous Dysplasia; 3.2.7.4 Osteofibrous Dysplasia; 3.2.7.5 Langerhans Cell Histiocytosis; 3.2.7.6 Erdheim-Chester Disease; 3.2.7.7 Chest Wall Hamartoma; 3.3 Molecular Pathogenesis; 3.3.1 AEG-1; 3.3.2 ATRX; 3.3.3 CDKN2A; 3.3.4 CTGF; 3.3.5 ET-1; 3.3.6 EXT1; 3.3.7 GNAS; 3.3.8 IDH1; 3.3.9 MDM2; 3.3.10 MEF2D; 3.3.11 MET; 3.3.12 NKD2; 3.3.13 PRIM1; 3.3.14 RUNX Family; 3.3.14.1 RUNX2; 3.3.14.2 RUNX3.
• 3.3.15 SATB23.3.16 TP53; 3.3.17 WIF-1; 3.4 Syndromes; 3.4.1 Li-Fraumeni Syndrome; 3.4.2 Mazabraud Syndrome; 3.4.3 McCune-Albright Syndrome; 3.4.4 Ollier Disease (Enchondromatosis); 3.4.5 Paget's Disease of Bone; 3.4.6 Retinoblastoma; 3.4.7 Rothmund-Thomson Syndrome; 3.4.8 Werner Syndrome; References; 4: Molecular and Cellular Mechanisms of Carcinogenesis in the Large Bowel; 4.1 Introduction; 4.2 Molecular Classification of Colorectal Cancer; 4.2.1 The Chromosomal Instability (CIN) Pathway; 4.2.2 Microsatellite Instability (MSI) Pathway and Lynch Syndrome (LS).